Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Catherine, Julie"'
Autor:
Julia Ouaknine Krief, Pierre Helly de Tauriers, Coraline Dumenil, Nathalie Neveux, Jennifer Dumoulin, Violaine Giraud, Sylvie Labrune, Julie Tisserand, Catherine Julie, Jean-François Emile, Thierry Chinet, Etienne Giroux Leprieur
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-8 (2019)
Abstract Background Recent data suggested a role of gut microbiota and antibiotic use on immune checkpoint inhibitors efficacy. We aimed to evaluate the impact of early use of antibiotic (EUA), blood microbiome and plasmatic citrulline (marker of the
Externí odkaz:
https://doaj.org/article/1ac16da7d72d4360a71cc08abea4aa14
Autor:
Jean-François Emile, Coraline Dumenil, Jennifer Dumoulin, Violaine Giraud, Sylvie Labrune, Catherine Julie, Thierry Chinet, Etienne Giroux Leprieur, Zofia Hélias-Rodzewicz, Paul Takam Kamga, Adrien Costantini, Alexandre Corjon, Simon Garinet
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 1 (2020)
Background Despite prolonged tumor response to immune checkpoint inhibitors (ICIs) for a subset of patients with advanced non-small cell lung cancer (NSCLC), a secondary resistance will occur for a majority of these patients. The understanding of lat
Externí odkaz:
https://doaj.org/article/03dd415e5a6e46c3a728013a99b7763e
Autor:
Adrien Costantini, Catherine Julie, Coraline Dumenil, Zofia Hélias-Rodzewicz, Julie Tisserand, Jennifer Dumoulin, Violaine Giraud, Sylvie Labrune, Thierry Chinet, Jean-François Emile, Etienne Giroux Leprieur
Publikováno v:
OncoImmunology, Vol 7, Iss 8 (2018)
Immune checkpoint inhibitors, as nivolumab, are used in advanced non-small cell lung cancer (NSCLC). However, no associated biomarker is validated in clinical practice with this drug. We investigated herein immune-related blood markers in patients wi
Externí odkaz:
https://doaj.org/article/da287e26617f4bc5a35c7d66a6731c6a
Autor:
Etienne Giroux Leprieur, Guillaume Herbretau, Coraline Dumenil, Catherine Julie, Violaine Giraud, Sylvie Labrune, Jennifer Dumoulin, Julie Tisserand, Jean-François Emile, Hélène Blons, Thierry Chinet
Publikováno v:
OncoImmunology, Vol 7, Iss 5 (2018)
Nivolumab is an anti-PD1 antibody, given in second-line or later treatment in advanced non-small cell lung cancer (NSCLC). The objective of this study was to describe the predictive value of circulating tumor DNA (ctDNA) on the efficacy of nivolumab
Externí odkaz:
https://doaj.org/article/b85a14a64db44194ab6d9474fb505465
Publikováno v:
Journal of Clinical and Diagnostic Research, Vol 10, Iss 3, Pp XD01-XD03 (2016)
The presence of an ALK (Anaplastic Lymphoma Kinase) rearrangement is a rare molecular feature in Non-Small Cell Lung Carcinoma (NSCLC), and concerns mainly non- or light smokers, young patients, with adenocarcinoma histological type. These tumours a
Externí odkaz:
https://doaj.org/article/4fa15762cb024c5cbc7c8308b2e207dd
Autor:
Hans Morreau, Marieke E. Ijsselsteijn, Catherine Sautès-Fridman, Florent Petitprez, Noel Filipe da Cunha Carvalho de Miranda, Ruud van der Breggen, Laetitia Lacroix, Catherine Julie, Wolf H. Fridman, Dina Ruano
Publikováno v:
British Journal of Cancer
British Journal of Cancer, Cancer Research UK, 2019, 120 (8), pp.815-818. ⟨10.1038/s41416-019-0421-x⟩
British Journal of Cancer, 120(8), 815-818. NATURE PUBLISHING GROUP
British Journal of Cancer, Cancer Research UK, 2019, 120 (8), pp.815-818. ⟨10.1038/s41416-019-0421-x⟩
British Journal of Cancer, 120(8), 815-818. NATURE PUBLISHING GROUP
International audience; In colorectal cancer (CRC), T-cell checkpoint blockade is only effective in patients diagnosed with mismatch repair-deficient (MMR-d) cancers. However, defects in Human Leukocyte Antigen (HLA) class I expression were reported
Autor:
Janick Selves, Jean-François Emile, Marie Laure Raffin-Sanson, Benoǐt Terris, Chiara Villa, Nicolas Girard, Jérôme Cros, Catherine Julie, Jean François Fléjou, Zofia Hélias-Rodzewicz, Jean Michel Coindre, Christine Lagorce-Pages, Anne Sophie de Lajarte-Thirouard, Nathalie Guedj, Florence Renaud, Dominique Cazals-Hatem, Simon Martin de Beauce, Cristi Marin, Henri Jean Garchon
Publikováno v:
Genes, Chromosomes and Cancer
Genes, Chromosomes and Cancer, Wiley, 2021, 60 (11), pp.723-732. ⟨10.1002/gcc.22981⟩
Genes, Chromosomes & Cancer
Genes, Chromosomes & Cancer, 2021, 60 (11), pp.723-732. ⟨10.1002/gcc.22981⟩
Genes, Chromosomes and Cancer, Wiley, 2021, 60 (11), pp.723-732. ⟨10.1002/gcc.22981⟩
Genes, Chromosomes & Cancer
Genes, Chromosomes & Cancer, 2021, 60 (11), pp.723-732. ⟨10.1002/gcc.22981⟩
International audience; Glomus tumors (GTs) are perivascular tumors mostly occurring in the distal extremities. Rare cases arise in the digestive tract and may be misdiagnosed with neuroendocrine or gastrointestinal stromal tumors. We aimed to specif
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d3dbe72d7e34942aae589121a0f893b
https://hal.archives-ouvertes.fr/hal-03434935
https://hal.archives-ouvertes.fr/hal-03434935
Autor:
Thierry Chinet, Camille Mehlman, Violaine Giraud, Adrien Costantini, Coraline Dumenil, Jean-François Emile, J. Ouaknine, Jennifer Dumoulin, Etienne Giroux Leprieur, Paul Takam Kamga, Catherine Julie
Publikováno v:
Cancers
Cancers, MDPI, 2021, 13 (5), pp.1107. ⟨10.3390/cancers13051107⟩
Volume 13
Issue 5
Cancers, Vol 13, Iss 1107, p 1107 (2021)
Cancers, MDPI, 2021, 13 (5), pp.1107. ⟨10.3390/cancers13051107⟩
Volume 13
Issue 5
Cancers, Vol 13, Iss 1107, p 1107 (2021)
Simple Summary Wnt and Hedgehog (Hh) pathways are associated with stemness profile and with resistance to anti-tumor therapies. Pre-clinical data have suggested a role of these pathways in resistance to immune checkpoint inhibitors (ICIs). Here we ev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::611ed353b97710105f7e964c5e13f05f
https://hal.archives-ouvertes.fr/hal-03171231
https://hal.archives-ouvertes.fr/hal-03171231
Autor:
Jennifer Dumoulin, Adrien Costantini, Violaine Giraud, Catherine Julie, Coraline Dumenil, Thierry Chinet, Jean-François Emile, Alexandre Corjon, Martin Rottman, J. Ouaknine, Etienne Giroux Leprieur, Paul Takam Kamga
Publikováno v:
Cancers
Cancers, Vol 13, Iss 97, p 97 (2021)
Cancers, MDPI, 2021, 13 (1), pp.1-12. ⟨10.3390/cancers13010097⟩
Cancers, MDPI, 2021, 13 (1), pp.97. ⟨10.3390/cancers13010097⟩
Volume 13
Issue 1
Cancers, Vol 13, Iss 97, p 97 (2021)
Cancers, MDPI, 2021, 13 (1), pp.1-12. ⟨10.3390/cancers13010097⟩
Cancers, MDPI, 2021, 13 (1), pp.97. ⟨10.3390/cancers13010097⟩
Volume 13
Issue 1
Immune checkpoint inhibitors (ICIs) are commonly used in patients with advanced non-small cell lung cancer (NSCLC). An unmet need remains for new biomarkers associated with ICIs. In this study, consecutive patients with advanced NSCLC treated with ni
Autor:
Adrien Costantini, Paul Takam Kamga, Thierry Chinet, Jean-François Emile, Etienne Giroux Leprieur, Simon Garinet, Sylvie Labrune, Alexandre Corjon, Zofia Hélias-Rodzewicz, Coraline Dumenil, Catherine Julie, Violaine Giraud, Jennifer Dumoulin
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 1 (2020)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer, BMJ Publishing Group 2020, 8 (1), ⟨10.1136/jitc-2020-000527⟩
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer, BMJ Publishing Group 2020, 8 (1), ⟨10.1136/jitc-2020-000527⟩
BackgroundDespite prolonged tumor response to immune checkpoint inhibitors (ICIs) for a subset of patients with advanced non-small cell lung cancer (NSCLC), a secondary resistance will occur for a majority of these patients. The understanding of late